Millions of older Americans in Medicare are about to receive a benefit that has never existed before: coverage of obesity drugs.
Starting Wednesday, eligible beneficiaries can get GLP-1s to treat obesity for a copay of just $50 per month. It’s a watershed move that could unlock a vast new patient population for Novo Nordisk and Eli Lilly and dramatically expand access to medications that were previously out of reach for many people ages 65 and above.
CNBC's Annika Kim Constantino reports.
Starting Wednesday, eligible beneficiaries can get GLP-1s to treat obesity for a copay of just $50 per month. It’s a watershed move that could unlock a vast new patient population for Novo Nordisk and Eli Lilly and dramatically expand access to medications that were previously out of reach for many people ages 65 and above.
CNBC's Annika Kim Constantino reports.